Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.

Cynthia Villarreal GarzaEdna Anakarenn Lopez-MartinezZuratzi Deneken-HernandezAntonio Maffuz-AzizJose Felipe Muñoz-LozanoRegina Barragan-CarrilloPier Ramos-EliasBrizio MorenoHector Diaz-PerezOmar Peña-CurielJose de Jesus Curiel-ValdezVeronica Bautista-Piña

Published in: PloS one (2020)

The EndoPredict test successfully assisted the clinical decision-making process in premenopausal patients, with a clinically significant change in overall decision-making, with the greatest impact seen in chemotherapy reduction, and a high rate of therapeutic adherence.

Keyphrases

decision making
postmenopausal women
high throughput
squamous cell carcinoma
metabolic syndrome
adipose tissue
radiation therapy
breast cancer risk
insulin resistance
early breast cancer